Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams (Q35209314)

7 August 2017

1 reference

title

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams (English)

1 reference

7 August 2017

H Bryan Brewer

1

1 reference

PubMed ID

12948873

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

23K-29K

1 reference

7 August 2017

4B

1 reference

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

The effect of erythromycin on the pharmacokinetics of rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Effect of itraconazole on the pharmacokinetics of rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

The effect of fluconazole on the pharmacokinetics of rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Risk for myopathy with statin therapy in high-risk patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

A general assessment of the safety of HMG CoA reductase inhibitors (statins).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

HMG-CoA reductase inhibitors and myotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900779-3

10.1016/S0002-9149(03)00779-3

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12948873